251 related articles for article (PubMed ID: 21950266)
1. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.
Fathi M; Barbasso Helmers S; Lundberg IE
J Intern Med; 2012 Jun; 271(6):589-97. PubMed ID: 21950266
[TBL] [Abstract][Full Text] [Related]
2. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis.
Hu C; Wu C; Yang E; Huang H; Xu D; Hou Y; Zhao J; Li M; Xu Z; Zeng X; Wang Q
Clin Rheumatol; 2019 Aug; 38(8):2181-2187. PubMed ID: 30888566
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
4. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
6. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker.
Hanaoka M; Katsumata Y; Kawasumi H; Kawaguchi Y; Yamanaka H
Mod Rheumatol; 2019 Jul; 29(4):625-632. PubMed ID: 30484723
[No Abstract] [Full Text] [Related]
7. Serum KL-6 in adult patients with polymyositis and dermatomyositis.
Kubo M; Ihn H; Yamane K; Kikuchi K; Yazawa N; Soma Y; Tamaki K
Rheumatology (Oxford); 2000 Jun; 39(6):632-6. PubMed ID: 10888708
[TBL] [Abstract][Full Text] [Related]
8. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
Chen F; Shu XM; Wang DX; Xie Y; Wang GC
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
Ihn H; Asano Y; Kubo M; Yamane K; Jinnin M; Yazawa N; Fujimoto M; Tamaki K
Rheumatology (Oxford); 2002 Nov; 41(11):1268-72. PubMed ID: 12421999
[TBL] [Abstract][Full Text] [Related]
12. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.
Fujisawa T; Suda T; Nakamura Y; Enomoto N; Ide K; Toyoshima M; Uchiyama H; Tamura R; Ida M; Yagi T; Yasuda K; Genma H; Hayakawa H; Chida K; Nakamura H
J Rheumatol; 2005 Jan; 32(1):58-64. PubMed ID: 15630726
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
14. [The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis].
Wang PZ; Guan JL; Han XH
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun; 31(6):417-20. PubMed ID: 19031800
[TBL] [Abstract][Full Text] [Related]
15. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.
Sugiyama Y; Yoshimi R; Tamura M; Takeno M; Kunishita Y; Kishimoto D; Yoshioka Y; Kobayashi K; Takase-Minegishi K; Watanabe T; Hamada N; Nagai H; Tsuchida N; Soejima Y; Nakano H; Kamiyama R; Uehara T; Kirino Y; Sekiguchi A; Ihata A; Ohno S; Nagaoka S; Nakajima H
Arthritis Res Ther; 2018 Jan; 20(1):7. PubMed ID: 29325580
[TBL] [Abstract][Full Text] [Related]
16. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
[TBL] [Abstract][Full Text] [Related]
17. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
Hozumi H; Fujisawa T; Nakashima R; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2019 May; 46(5):509-517. PubMed ID: 30647164
[TBL] [Abstract][Full Text] [Related]
19. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
